| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
2,3-Dinor-11 Beta-Prostaglandin F2 Alpha, Urine
MessageAlthough a random urine is acceptable, the preferred specimen is a 24 hour collection.
Test Code
LAB00930
Alias/See Also
LAB00930
Mayo TC: 23BPR - Random Urine / 23BPT - 24 Hour Urine
2,3 Dinor
Mayo TC: 23BPR - Random Urine / 23BPT - 24 Hour Urine
2,3 Dinor
CPT Codes
84150
Includes
2,3-dinor 11 Beta-prostaglandin F2a
Creatinine
Creatinine
Preferred Specimen
5 mL of a Random or 24 Hour Urine Collection - For a 24 Hour urine, record the total volume and duration of collection.
No Preservatives.
No Preservatives.
Patient Preparation
Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to collecting a specimen.
Minimum Volume
3 mL of a Random or 24 Hour Urine Collection
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated: 14 days
Methodology
2,3-Dinor 11 Beta-Prostaglandin F2 Alpha - LC-MS/MS
Creatinine - Enzymatic Colorimetric Assay
Report Available
3-8 days
Limitations
Elevated levels of 2,3-dinor-11 beta-prostaglandin F2 alpha (2,3 BPG) in urine are not specific for systemic mast cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative disease in the absence of diffuse mast cell proliferation.
Systemic mast cell disease is a heterogeneous disease, and some patients may not have elevated 2,3 BPG in urine.
Systemic mast cell disease is a heterogeneous disease, and some patients may not have elevated 2,3 BPG in urine.
Reference Range
2,3-Dinor-11 Beta-Prostaglandin F2 Alpha:
<1802 pg/mL creatinine
<1802 pg/mL creatinine
Clinical Significance
2,3-Dinor-11beta-prostaglandin F2 alpha is the most abundant metabolic product of prostaglandins released by activated mast cells. Systemic mastocytosis (SM) is a disease in which clonally derived mast cells accumulate in peripheral tissues. Degranulation of these mast cells releases large amounts of histamines, prostaglandins, leukotrienes, and tryptase.
The World Health Organization diagnostic criteria for SM require the presence of elevated mast cell counts on a bone marrow biopsy and 1 of the following minor criteria:
- Abnormal mast cell morphology
- KIT Asp816Val mutation
- CD25-positive mast cells
- Serum tryptase greater than 20 ng/mL.
Alternatively, SM diagnosis can be made with the presence of 3 minor criteria in the absence of abnormal bone marrow studies.
Measurement of mast cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of serum tryptase, urinary N-methylhistamine (NMH), 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG), or leukotriene E4 (LTE4) are consistent with the diagnosis of systemic mast cell disease.
The World Health Organization diagnostic criteria for SM require the presence of elevated mast cell counts on a bone marrow biopsy and 1 of the following minor criteria:
- Abnormal mast cell morphology
- KIT Asp816Val mutation
- CD25-positive mast cells
- Serum tryptase greater than 20 ng/mL.
Alternatively, SM diagnosis can be made with the presence of 3 minor criteria in the absence of abnormal bone marrow studies.
Measurement of mast cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of serum tryptase, urinary N-methylhistamine (NMH), 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG), or leukotriene E4 (LTE4) are consistent with the diagnosis of systemic mast cell disease.
Performing Laboratory
Mayo Cinic Laboratories